Business Wire India
First-in-class ompenaclid (RGX-202) currently in Phase II development for RAS-mutated advanced or metastatic colorectal cancer
Collaboration includes exclusive license outside the...
Business Wire India
Results from the EVOLUTION clinical trials showed evobrutinib did not meet its primary endpoint of annualized relapse rate for up to...
Business Wire India
Pimicotinib (ABSK021) is currently in a global Phase III study in tenosynovial giant cell tumor (TGCT)
Merck to receive an exclusive...
Business Wire India
Not intended for US-, Canada- or UK-based media
Partnerships with BenevolentAI and Exscientia to drive accelerated drug discovery with higher probability of...
